Edition:
United States

Health News

Photo

Mylan faces scrutiny over EpiPen profit data shown to Congress 3:39pm EDT

Mylan NV faced questions on Monday about the profit on its EpiPen emergency allergy treatment, following a report that the company makes 60 percent more on the injector than it had told Congress.

More Headlines

Photo

Sanofi may win U.S. approval of $3 billion eczema drug by March

French drugmaker Sanofi  and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.

3:26am EDT

Care home nurses need training for unique role

(Reuters Health) - The most important thing nurses provide to nursing home patients are dignity, personhood and quality of life, but training in these aspects of care is lacking, according to a U.K. study.

12:57pm EDT

Clovis short sellers undaunted as stock price surges

NEW YORK Clovis Oncology Inc's share price has doubled in the past month, fueled by positive developments for the company's experimental cancer drug and takeover speculation. But some investors also appear to be increasing bets against the stock.

3:05pm EDT
Photo

Vela Diagnostics gets emergency U.S. authorization for Zika test

Vela Diagnostics said its test for the Zika virus had received "emergency use authorization" from the U.S. Food and Drug Administration.

8:27am EDT

Health Watch Graphics